Q & M Dental reported FY 2025 revenue of SGD 197.2 million (+9%) and profit after tax of SGD 9.9 million (-22%), with profit attributable to shareholders of SGD 9.3 million (-35%). EBITDA was SGD 37.8 million, and FY 2025 EPS was 0.98 cents (fully diluted: 0.98 cents). In 2H 2025, revenue was SGD 108.8 million (+21%) and profit after tax was SGD 5.9 million; profit attributable to shareholders was SGD 5.5 million. The group cited higher core dental revenue driven mainly by consolidating Aoxin Q & M from an equity-accounted associate to a subsidiary in May 2025 and higher contributions from Singapore dental clinics, while “other businesses” revenue fell to SGD 1.0 million (-55%) due to the cessation of its medical laboratory in September 2024 following the expiry of its clinical laboratory service licence. As at 31 Dec 2025, Q & M Dental had cash and cash equivalents of SGD 117.1 million, total assets of SGD 352.4 million, and total liabilities of SGD 216.6 million. The group also reported 110 dental outlets and 5 medical outlets in Singapore, 37 dental outlets in Malaysia, and in China 7 dental polyclinics and 7 dental hospitals (among other facilities). It issued SGD 130.0 million of 3.95% notes on 10 July 2025, and said it consolidated both Aoxin Q & M and EM2AI into subsidiaries during FY 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q & M Dental Group (Singapore) Limited published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 43R0TJUKNIG58SVJ) on February 28, 2026, and is solely responsible for the information contained therein.